Technical notes: Cost for HCV cure (Lowest average FOB price for 3 months of pangenotypic regimens)

Technical notes: Cost for HCV cure (Lowest average FOB price for 3 months of pangenotypic regimens)

Description

Description of indicator: This indicator represents the lowest "Freight on Board" price of a full course of HCV cure. This price represents the price at the time of export but does not include all shipping, customs, storage, and distributor-associated costs that would also be incurred by the Ministry of Health or other procurement agency.

Sources

Survey/reported

The source of this price information is: CHAI (2020) Hepatitis C Market Report. Issue 1. Available at: https://www.globalhep.org/sites/default/files/content/resource/files/2020-05/Hepatitis-C-Market-Report_Issue-1_Web.pdf

The primary data source for this report is the India Import Export Database. Prices represent "freight on board" prices at time of export from Indian generic manufacturers. According to CHAI, "FOB prices are the prices at which the supplier exports the drug from the country. These prices do not include shipping, customs, storage and distributor-associated costs. Usually there are in-country costs added to the FOB price, resulting in a higher final price to the buyer." Therefore, the prices reported should not be considered the final price paid for 3 months of HCV cure.

In Appendix 7, CHAI reports the average price per bottle (28 pills) of key DAAs from 2016-2019. The dashboards report on the lowest price of a DAA pangenotypic regimen and multiply this price by three to estimate the full course of 3 months of treatment. 

Additional details are available in Appendix 8 of the CHAI Market Report.

Modelled

No modelled estimates currently available.